Meet the team
Prosemble is led by a team of experts with deep experience in science, finance, and technology…
FOUNDERS
Dr. Julien Bergeron
CEO/ CSO
Dr. Julien Bergeron is an internationally recognised expert in protein biochemistry and biophysics, having received advanced training in the USA and Canada. As a associate professor at King’s College London, he leads a research team focused on bacterial virulence and antibiotic resistance.
Dr. Bergeron has successfully secured over £4M in research funding and has collaborated with Isomorphic Labs/Google DeepMind on AlphaFold3.
His expertise and experience in managing large research teams, combined with access to cutting-edge research facilities, position him ideally to lead the technical development of Prosemble’s nanoparticle drug delivery platform.
Inna Zhuranskaya CDir
CFO/COO
Ms. Inna Zhuranskaya brings over 20 years of in PE/VC experience, having held CEO/CIO roles at Allrise Capital and Yoo Group, as well as senior positions at Deutsche Bank, Bank of America, and GIC, Singapore’s sovereign wealth fund. She is a Chartered Director at the IOD, a Chartered Member of the Institute for Securities & Investments, and the University of Cambridge and the LSE’s graduate.
She has raised over £2B and led several groundbreaking transactions, including JVs with major institutional investors, such as European and Middle Eastern sovereign wealth and pension funds. Ms. Zhuranskaya has served on the boards of Alkor Bio Group and Astra Biotech GmbH, where she oversaw a JV with the University of Newcastle focused on mesenchymal stem cells’ treatment for ischemic stroke. Her deep expertise in capital raising, structuring, and leading cross-functional teams will be instrumental in securing funding and driving the business strategy for the commercialisation of Prosemble’s technology.
TEAM
Dr. Ludovico Pipito
AI/ML Lead. Head of Computational Chemistry (Acting CTO)
Dr. Ludovico Pipito is a computational chemist and ML engineer developing cutting-edge solutions for drug discovery. At Prosemble he bridges biochemistry and AI to reduce chemotherapy toxicity, while maintaining his academic role as Research Fellow at Coventry University. He pioneered the multiple-walker supervised molecular dynamics (mwSuMD), an unbias method to accelerate 100x the sampling of rare biochemical events, and developed scalable QM-refined HTVS pipelines for drug discovery and FEP evaluation. He also applies computational chemistry and ML to unveil the biological mechanism of depalmitoylating enzymes.
He actively collaborates with AstraZeneca on antigen-antibody epitope modelling (EpiFinder) and LLM-based molecule generation. He is specialised in drug discovery for cancer, while authoring numerous publications on SARS-CoV-2 therapeutics, HIV inhibitors, and innovative computational method development, building scalable pipelines that combine QM, FEP, and neural networks to industry standards.
Dr. Alexandra Parker
Director
Dr. Alexandra Parker is an accomplished structural biologist and biochemist with a PhD in Molecular Biology and Biotechnology from the University of Sheffield, where her research focused on chromosome segregation in Vibrio Cholerae, employing a multidisciplinary approach including cryo-electron microscopy and X-ray crystallography, with findings published in the Nature Communications.
Dr. Parker further developed her expertise in structural biology as a Postdoctoral Research Associate at King’s College London, broadening her focus to membrane proteins and investigating complexes involved in membrane maintenance and auto-translocation in Gram-negative bacteria. As a Senior Scientist at Domainex, Dr. Parker brings extensive experience across academia and industry, particularly in protein expression, purification, and structural determination, playing a key role in advancing scientific innovation in drug discovery.
Dr. Sadie Hallett
Senior Scientist
Dr. Sadie Hallett is a Senior Scientist at Prosemble with a strong academic background in molecular and cellular biology. Her PhD was focused on kinase signaling via RNA-binding proteins in cancer.
Prior to this, Dr.Hallett completed an MRes in Biomedical and Translational Science at King’s, contributing to publications on antibody responses to SARS-CoV-2 and the AstraZeneca COVID-19 vaccine, and an MBio in Biochemistry at the University of Warwick.
Tadas Vilkas
IT Infrastructure Lead
Mr. Tadas Vilkas is currently on secondment to Prosemble, bringing over a decade of experience in IT service management, operations, and project delivery. He serves as a Project Manager at SKAYLINK.LT leading complex infrastructure and integration projects with a strong focus on reliability and business continuity.
Mr. Vilkas has previously held senior IT roles at Lantmännen and Vaasan Oy, where he managed service delivery across international teams and oversaw critical incident and problem management processes. He holds MSc Information Technology from the Vilnius University Šiauliai Academy with a specialisation in signal technologies and IT systems.
SCIENTIFIC ADVISORY BOARD
Serge Platonow
Non-Executive Chairman
Mr. Serge Platonow is an accomplished executive with extensive experience in PE and investment management. He serves as Non-Executive Chairman at Prosemble. Mr. Platonow is also a Principal at the Hayrish Group, a investment firm specialising in real estate and PE. Prior to this, he held senior leadership positions at Chelsfield, a global investment and development firm, where he served as Managing Director for Europe, overseeing major capital projects.
Mr. Platonow has also worked at Colony Capital (now DigitalBridge), a leading investment firm with over £50B in AUM where he was CIO of its real estate and infrastructure arm, Colyzeo Investment Management. He has served on the boards of prestigious organisations, including Paris Saint-Germain Football Club and Lucia SA. Mr. Platonow holds an MBA from INSEAD, an MSc from the MIT. He is the son of the late Nicolas Platonow, a prominent toxicologist and advisor to the Canadian government.
Professor Amichay Meirovitz
Science Advisor
Professor Meirovitz is Chairman of Oncology at Soroka University Medical Centre and Professor at Ben-Gurion University. A specialist in radiation oncology and internal medicine, he focuses on head and neck, urological, gynaecological, and lung cancers. He leads advanced radiotherapy techniques like IMRT, SBRT, and brachytherapy.
His research centres on molecular and radiation biology, especially the tumour microenvironment. With over 20 years of experience, he is passionate about innovation and translational cancer care.
Dr. Ian Durrant
Commercialisation Advisor
Dr. Durrant is IP & Licensing Manager at King’s College London with over 17 years’ leadership experience at Oxford Immunotec.
He has expertise in pharmaceuticals, medical devices, molecular biology, and patent law, gained through senior roles including Director of Intellectual Property Licensing.
Professor Susana Banerjee
Science Advisor
Professor Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust, and Reader in Women’s Cancers at the ICR. She specialises in ovarian, advanced endometrial, and cervical cancers, leading clinical trials on targeted therapies.
She has won awards like the Avon Breast Cancer Crusade Fellowship and San Antonio Breast Cancer Symposium Novartis Award. Active in ESMO and other groups, her research focuses on personalising treatments for gynaecological cancers, including rare types.
Professor Miraz Rahman
Science / Commercialisation Advisor
Professor Rahman is Professor of Medicinal Chemistry at King’s College London with 15+ years in drug discovery. He specialises in anticancer and anti-infective agents, collaborating with Public Health England on antibiotic resistance.
He holds 12 patents, has published 60+ papers, and co-founded two oncology biotech firms.
CONSULTANTS
Dr. Agata Nyda
Breast and Lung Cancer Advisor
Dr. Nyda is a cell biologist and Founder of SynLaia Innovations, with 13+ years in cancer research and early-stage innovation. She advises Migration Biotherapeutics and the European Commission.
Dr. Nyda will support Prosemble on in-vitro validation of targeted compounds for breast and lung cancer, data interpretation, and experimental planning.
John Finnemore
Legal Council
Mr. John Finnemore is a Partner in the CMS Corporate Team (CMS Cameron McKenna Nabarro Olswang) and serves as the Legal Council for Prosemble. He is a specialist in VC, PE and M&A, with a particular focus on advising clients in the technology sector through all funding rounds to eventual exit.
Mr. Finnemore trained with a US law firm and has worked for international law firms throughout his career. He has substantial experience in PE/VC and is ranked in both the Chambers and Legal 500 guides for his expertise in this space.
Declan Murtagh
Digital Consultant
Mr. Declan Murtagh is a digital and innovation consultant and co-founder of Brilliant Red Digital, specialising in helping startups and SMEs grow and scale through smart, data-driven strategies. With a background in marketing and innovation, Declan works on projects focused on customer discovery, market validation, and brand development—including building impactful websites and digital experiences.
He supports businesses through every stage of their journey, from launching new products to scaling through social media, SEO, paid campaigns, and content marketing.
Raimonda Karpavice
Account / Tax Council
Ms. Raimonda Karpavice is an accomplished finance and accounting professional currently serving as Account/Tax Council at Prosemble. With a First-Class BA in Business and Management from the University of Northampton, Ms. Karpavice brings a strong foundation in business principles combined with hands-on experience across finance and operations. She has built a solid career through progressively senior roles at firms including Moore Kingston Smith, Shipleys LLP, and Konsus Ltd, where she was responsible for VAT reporting, CIS submissions, bank and balance sheet reconciliations, P&L analysis, statutory accounts preparation, and payroll.
Ms. Karpavice is known for her strong leadership and analytical skills, with a proven track record of exceeding KPIs and delivering results. She has a particular interest in data analysis and strategic planning. Her experience spans both corporate finance and business operations, making her uniquely positioned to understand and drive end-to-end business efficiency.
Through Our Science We Are Transforming Cancer Treatment for Chemotherapy Patients
